Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

BACKGROUND: Enzalutamide (Enz) has shown limited bioavailability via oral administration. Castration-resistant prostate cancer (CRPC) is frequent among patients receiving 18–24 months of androgen deprivation therapy. The nonsteroidal anti-androgen enzalutamide (Enz) used in the treatment of prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wenjun, Chen, Jiyuan, Gong, Chunai, Wang, Yuanyuan, Gao, Yuan, Yuan, Yongfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079409/
https://www.ncbi.nlm.nih.gov/pubmed/32188463
http://dx.doi.org/10.1186/s12951-020-00607-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079409/
https://www.ncbi.nlm.nih.gov/pubmed/32188463
http://dx.doi.org/10.1186/s12951-020-00607-4

Ejemplares similares